Kick-starting the cancer-immunity cycle by targeting CD40

OncoImmunology

Volumn 4, Issue 7, 2015, Pages 1-3

  Ellmark, P ^a,b   Mangsbo, S M ^c   Furebring, C ^a   Totterman T H ^c   Norlen P ^a  

^a Alligator Bioscience AB   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Agonistic antibody; CD40; Immunooncology; PD 1

Indexed keywords

ADC 1013; ANTINEOPLASTIC AGENT; CD40 ANTIGEN; CHECKPOINT KINASE INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; RO 7009789; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84944453397     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1011484     Document Type: Article

References (10)

1. Naidoo J, Page DB,Wolchok JD. Immune modulation for cancer therapy. Br J Cancer 2014; 111:2214-9; PMID:25211661; http://dx.doi.org/10.1038/bjc.2014. 348.
2. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j. immuni.2013.07.012.
3. Mangsbo SM, Broos S, Fletcher E, Veitonmaki N, Furebring C, Dahlen E, Norlen P, Lindstedt M, Totterman TH, Ellmark P. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity. Clin Cancer Res 2015; 21:1115-26. pii: clincanres. 0913.2014.
4. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013;19 :1035-43; PMID:23460534; http://dx.doi.org/ 10.1158/1078-0432.CCR-12-2064.
5. Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 2008;20:1467-79; PMID:18824504; http://dx.doi. org/10.1093/intimm/dxn104.
6. Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 2011; 17:2270-80; PMID:21389097; http://dx.doi. org/10.1158/1078-0432.CCR-10-2888.
7. Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res 2014; 2:80-90; PMID:24778163; http://dx.doi.org/ 10.1158/2326-6066.CIR-13-0067.
8. Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014; 20: 1747-56; PMID:24691639; http://dx.doi.org/10.1158/1078-0432.CCR-13-2116.
9. Furness AJ, Vargas FA, Peggs KS, Quezada SA. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol 2014; 35:290-8; PMID:24953012; http:// dx.doi.org/10.1016/j.it.2014.05.002.
10. Zippelius A, Schreiner J, Herzig P2, Müller P. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015; 3: 236-44.